{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:58:53Z","timestamp":1790056733778,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1093\/jac\/dkz050","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T20:12:08Z","timestamp":1547669528000},"page":"1751-1753","source":"Crossref","is-referenced-by-count":42,"title":["Isavuconazole brain penetration in cerebral aspergillosis"],"prefix":"10.1093","volume":"74","author":[{"given":"F","family":"Lamoth","sequence":"first","affiliation":[{"name":"Service of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland"},{"name":"Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mercier","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Pagani","sequence":"additional","affiliation":[{"name":"Service of Intensive Care Medicine, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Pantet","sequence":"additional","affiliation":[{"name":"Service of Intensive Care Medicine, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Maduri","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Service of Neurosurgery, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Guery","sequence":"additional","affiliation":[{"name":"Service of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Decosterd","sequence":"additional","affiliation":[{"name":"Service and Laboratory of Clinical Pharmacology, University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"key":"2019051708100306500_dkz050-B1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2019051708100306500_dkz050-B2","doi-asserted-by":"crossref","first-page":"e01537","DOI":"10.1128\/AAC.01537-18","article-title":"Isavuconazole for treatment of experimental fungal endophthalmitis caused by Aspergillus fumigatus","volume":"62","author":"Guest","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708100306500_dkz050-B3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JCM.03176-13","article-title":"Isavuconazole treatment of a patient with disseminated mucormycosis","volume":"52","author":"Peixoto","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2019051708100306500_dkz050-B4","author":"Schwartz"},{"key":"2019051708100306500_dkz050-B5","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1128\/AAC.00229-16","article-title":"Isavuconazole is effective for the treatment of experimental cryptococcal meningitis","volume":"60","author":"Wiederhold","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708100306500_dkz050-B6","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00404-10","article-title":"Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin","volume":"54","author":"Decosterd","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708100306500_dkz050-B7","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708100306500_dkz050-B8","doi-asserted-by":"crossref","first-page":"e01292","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708100306500_dkz050-B9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1086\/377131","article-title":"Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients","volume":"37","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2019051708100306500_dkz050-B10","doi-asserted-by":"crossref","first-page":"e01034","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/6\/1751\/28666740\/dkz050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T12:10:22Z","timestamp":1558095022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/6\/1751\/5315664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,11]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz050","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,2,11]]}}}